Drugs / Polyethylene glycol 400
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06375343 | Jan 2026 → Jan 2027 expected | dry eye syndrome | Laboratorios Sophia S.A de C.V. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06379685 | Dec 2025 → Dec 2026 expected | dry eye syndrome | Laboratorios Sophia S.A de C.V. | Not yet recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00493662 | — | dry eye syndrome | Innovative Medical | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT05660681 | Dec 2022 → Aug 2023 | dry eye syndrome | Calm Water Therapeutics LLC | Completed | No outcome recorded |
| — | NCT04970329 | Jul 2021 | dry eye syndrome | University of Faisalabad | Unknown | No outcome recorded |
| Comparator or background therapy5 trials | ||||||
| Phase 4 | NCT07676084 Comparator | Jun → Oct 2026 expected | dry eye syndrome | Andover Research Eye Institute | Recruiting | No outcome recorded |
| Phase 4 | NCT05292755 Comparator | Apr → May 2022 | dry eye syndrome | University of Florida | Completed | Missed primary |
| Phase 4 | NCT04708366 Comparator | Feb 2021 → Mar 2022 | colonic disorder | University of Bologna | Unknown | No outcome recorded |
| Phase 4 | NCT00756678 Comparator | Sep 2008 → Aug 2009 | dry eye syndrome | Allergan | Completed | No outcome recorded |
| — | NCT00681265 Comparator | Jun → Aug 2008 | dry eye syndrome | Calm Water Therapeutics LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Polyethylene glycol 400 | “Systane brand artificial tears containing 0.4% polyethylene glycol 400 and 0.3% propylene glycol will be self-administered three times a day in each eye by the participants for...” NCT05292755 ↗8“Propylene glycol 0.3% - Polyethylene glycol 400 0.5% - Glycerin 0.2%. Ophthalmic solution.” NCT06375343 ↗ “CWT-f-002: Active Ingredients are glycerin 0.7% and polyethylene glycol 400 0.4%.” NCT05660681 ↗ “Propylene glycol 0.3% - Polyethylene glycol 400 0.3%. Ophthalmic solution.” NCT06379685 ↗ “Polyethylene glycol 400” NCT00756678 ↗ |
| Known as | Macrogol 400 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04708366 ↗ |
| Route | Topical | “glycerin 0.7%/PEG 400 0.3% lubricant eye drops” NCT05660681 ↗ |